Tuesday, March 04, 2025 | 07:20 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Aurobindo Pharma stock: Good growth in Europe may cushion downside

Analysts said given the strong European prospects and as most concerns relating to unit-IV are priced in, downside was limited for the stock

Aurobindo Pharma
Premium

Source: BS Research Bureau

Ujjval Jauhari New Delhi
Aurobindo Pharma continues to be under pressure on the bourses owing to the US Food and Drug Administration’s (US FDA’s) observations to its unit-IV facility at Hyderabad.
 
On Monday, Aurobindo confirmed that the unit has received nine observations between February 12 and February 20. As a result, some caution will prevail till complete clearance is given to the unit, even as analysts say the observations are not very serious.
 
The firm’s unit-IV makes injectables and accounts for a third of Aurobindo’s pending abbreviated new drug applications (ANDAs), analysts said. An ANDA contains data, which is submitted to the

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in